PULMONARY PHARMACOLOGY & THERAPEUTICS

metrics 2024

Elevating standards in pulmonary pharmacology and therapy.

Introduction

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

Metrics 2024

SCIMAGO Journal Rank0.79
Journal Impact Factor3.30
Journal Impact Factor (5 years)2.80
H-Index81
Journal IF Without Self3.30
Eigen Factor0.00
Normal Eigen Factor0.40
Influence0.64
Immediacy Index0.50
Cited Half Life8.50
Citing Half Life5.70
JCI0.84
Total Documents1856
WOS Total Citations2818
SCIMAGO Total Citations15360
SCIMAGO SELF Citations642
Scopus Journal Rank0.79
Cites / Document (2 Years)3.26
Cites / Document (3 Years)3.09
Cites / Document (4 Years)3.19

Metrics History

Rank 2024

Scopus

Pulmonary and Respiratory Medicine in Medicine
Rank #39/155
Percentile 74.84
Quartile Q2
Pharmacology (medical) in Medicine
Rank #69/272
Percentile 74.63
Quartile Q2
Biochemistry (medical) in Medicine
Rank #23/72
Percentile 68.06
Quartile Q2

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 118/354
Percentile 66.80
Quartile Q2
RESPIRATORY SYSTEM
Rank 32/100
Percentile 68.50
Quartile Q2

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 116/354
Percentile 67.23
Quartile Q2
RESPIRATORY SYSTEM
Rank 34/101
Percentile 66.34
Quartile Q2

Quartile History

Similar Journals

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Advancing respiratory health through cutting-edge research.
Publisher: AMER THORACIC SOCISSN: 1073-449XFrequency: 24 issues/year

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

Therapeutic Advances in Respiratory Disease

Unlocking Insights for Enhanced Patient Outcomes
Publisher: SAGE PUBLICATIONS LTDISSN: 1753-4658Frequency: 1 issue/year

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

LUNG

Advancing knowledge in pulmonary health since 1959.
Publisher: SPRINGERISSN: 0341-2040Frequency: 6 issues/year

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

Annals of Thoracic Medicine

Connecting researchers and practitioners in thoracic health.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1817-1737Frequency: 4 issues/year

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

PEDIATRIC PULMONOLOGY

Advancing pediatric respiratory health through innovative research.
Publisher: WILEYISSN: 8755-6863Frequency: 12 issues/year

Pediatric Pulmonology is a leading journal published by Wiley, dedicated to advancing the field of pediatric respiratory medicine. With an impressive impact factor and a commitment to excellence since its inception in 1985, this quarterly publication reaches researchers, clinicians, and healthcare professionals interested in the latest findings and practices concerning pediatric pulmonary health. The journal has achieved notable rankings in prestigious databases, including Q1 in Pediatrics, Perinatology, and Child Health, and Q2 in Pulmonary and Respiratory Medicine, reflecting its high-quality contributions to the field. Celebrated for its rigorous peer-review process, Pediatric Pulmonology serves as a vital platform for disseminating significant research, clinical studies, and innovative approaches to the management of respiratory conditions in infants, children, and adolescents. This journal not only provides valuable insights but also fosters collaboration among professionals dedicated to enhancing the care and outcomes for young patients. Access to this resource is available through institutional subscriptions, further ensuring widespread dissemination of crucial research findings.

Egyptian Journal of Bronchology

Connecting researchers and practitioners in bronchial health.
Publisher: SPRINGERISSN: 1687-8426Frequency: 4 issues/year

Egyptian Journal of Bronchology, published by SPRINGER, is a premier open access journal dedicated to advancing the field of respiratory medicine, particularly focusing on bronchial diseases and disorders. Since its establishment in 2013, this journal has provided a platform for the dissemination of high-quality research articles, systematic reviews, and clinical studies, making significant contributions to the understanding and management of bronchological conditions. With its commitment to open access, the journal ensures that research findings are readily available to a global audience, fostering knowledge exchange among researchers, healthcare professionals, and students alike. The Egyptian Journal of Bronchology serves as an essential resource in the field, reflecting a growing emphasis on accessible scientific knowledge and collaborative research in respiratory health.

Lancet Respiratory Medicine

Innovating treatment strategies for respiratory diseases.
Publisher: ELSEVIER SCI LTDISSN: 2213-2600Frequency: 12 issues/year

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Respiratory Investigation

Advancing knowledge in Pulmonary and Respiratory Medicine.
Publisher: ELSEVIERISSN: 2212-5345Frequency: 6 issues/year

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Empowering respiratory care with breakthrough findings.
Publisher: MARY ANN LIEBERT, INCISSN: 1941-2711Frequency: 6 issues/year

The Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by MARY ANN LIEBERT, INC, is a distinguished journal dedicated to advancing the field of aerosol medicine and pharmacology. With an ISSN of 1941-2711 and E-ISSN 1941-2703, the journal has established itself as an essential resource for researchers and professionals specializing in pharmaceutical sciences and pulmonary medicine. Ranking in the Q2 category across multiple disciplines, including Pharmaceutical Science and Pulmonary and Respiratory Medicine, it holds notable Scopus rankings, with a percentile of 78th in Pulmonary and Respiratory Medicine. The journal offers open access options, ensuring that cutting-edge research is readily available to a global audience. With converged years from 2008 to 2024, the Journal of Aerosol Medicine and Pulmonary Drug Delivery continues to serve as a vital platform for disseminating innovative research findings, clinical practice insights, and technological advancements in drug delivery systems, thereby significantly impacting therapeutic strategies for respiratory diseases.

Zeitschrift fur Pneumologie

Catalyzing Change in Pulmonary Health Research
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.